Biotech

All Articles

FDA locations Kezar lupus test in hold observing 4 individual fatalities

.The FDA has actually put Kezar Life Sciences' lupus test on hold after the biotech flagged 4 deaths...

Phase 3 Intellectual Rock trial hits SMA target, sending out stock up 200%

.A phase 3 test of Intellectual Stone's spine muscle degeneration (SMA) applicant has actually attac...

CAMP 4 is most recent to eye IPO, while Upstream point out $182M program

.RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, along with inflammation-...

Galecto buys leukemia medication, loses bone cancer asset in pivot

.A year after the failing of an idiopathic pulmonary fibrosis candidate sent out Galecto on a look f...

Judo throws down $100M to knock out renal health condition

.Taking the floor covering is actually Judo Biography, a promising biotech armed with $100 thousand ...

AstraZeneca pays CSPC $100M for preclinical heart disease medicine

.AstraZeneca has paid off CSPC Drug Team $100 million for a preclinical heart disease medication. Th...

Zephyrm finds Hong Kong IPO to finance period 3 cell treatment trials

.Zephyrm Bioscience is actually gusting toward the Hong Kong stock market, submission (PDF) for an I...

Frazier Lifestyle Sciences gathers $630M for small, mid-cap biotechs

.Frazier Life Sciences has actually sourced a better $630 million for its own fund focused on small ...

GigaGen gets as much as $135M BARDA bucks to beat botulism

.Antitoxin enthusiast GigaGen, a subsidiary of Spanish biopharma Grifols, is ramping up its technolo...

GPCR firm Septerna declare IPO on durability of preclinical data

.Septerna is about to find out just how a biotech without "any sort of meaningful medical records" m...